Wilson Sonsini Goodrich & Rosati has advised Khartis Therapeutics. Khartis Therapeutics, a biotechnology company specializing in oral small molecule medicines for immunological and chronic diseases, has...
Khartis Therapeutics Raises $50 Million in Series B Financing for Immunology Pipeline Expansion
Braveheart Bio Raises $439.9 Million in Upsized Initial Public Offering
Goodwin Procter and Wilson Sonsini Goodrich & Rosati have advised Braveheart Bio. Braveheart Bio, a clinical-stage biopharmaceutical company developing therapeutics for hypertrophic cardiomyopathy (HCM) and other...
Expedition Therapeutics Raises $115 Million in Series B Financing to Advance COPD Treatment
Wilson Sonsini Goodrich & Rosati has advised Expedition Therapeutics. Expedition Therapeutics, a clinical-stage biotechnology company focused on therapies for inflammatory and respiratory diseases, has closed an...
argenx Acquires Forte Biosciences for $2.2 Billion, Adding First-in-Class Anti-CD122 Antibody to Immunology Pipeline
Freshfields LLP has advised argenx. Wilson Sonsini Goodrich & Rosati, P.C. has advised Forte Biosciences. Argen NV ADR (NASDAQ: ARGX) and Forte Biosciences, Inc. (NASDAQ: FBRX)...
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals in $10 Billion All-Cash Deal
Kirkland & Ellis has advised Vertex Pharmaceuticals Incorporated. Paul, Weiss, Rifkind, Wharton & Garrison LLP and Morrison Foerster LLP have advised Crinetics Pharmaceuticals, Inc. Wilson Sonsini...
Legend Biotech Announces $226 Million Public Offering of ADSs
Wilson Sonsini Goodrich & Rosati, Professional Corporation has advised the underwriters with respect to U.S. federal securities law and New York State law. Cooley LLP has...
Contraline Secures $92.5 Million Series B Funding for Late-Stage Development of Male Contraceptive
Fenwick & West has advised Contraline. Wilson Sonsini Goodrich & Rosati has advised BVF Partners L.P. on IP matters. Contraline, a clinical-stage biopharmaceutical company focused on...
UCB to Acquire Candid Therapeutics in $2.2 Billion Deal
Cooley and Wilson Sonsini Goodrich & Rosati have advised Candid Therapeutics. Covington & Burling has represented UCB. UCB, a global biopharmaceutical company, has announced a definitive...
Odyssey Therapeutics Announces $304 Million Upsized IPO and Private Placement
Covington and Wilson Sonsini have advised Odyssey Therapeutics. Cooley has advised the underwriters. Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases,...
Lilly Acquires Centessa Pharmaceuticals for Up to $7.8 Billion to Bolster Neuroscience Portfolio
Kirkland & Ellis has advised Eli Lilly and Company. Goodwin Procter and Wilson Sonsini Goodrich & Rosati have advised Centessa Pharmaceuticals plc. Eli Lilly and Company...
Rallybio to Acquire Candid Therapeutics in Merger and $505 Million Financing
Ropes & Gray has advised Rallybio. Wilson Sonsini Goodrich & Rosati has advised Candid Therapeutics on patent matters. Rallybio Corporation and Candid Therapeutics have entered into...
Forte Biosciences Announces $150 Million Public Offering of Common Stock
Wilson Sonsini Goodrich & Rosati has advised Forte Biosciences. Paul Hastings LLP has advised Guggenheim Securities and Barclays. Forte Biosciences, Inc., a clinical-stage biopharmaceutical company specializing...